Clinical trial NCT03059264: Trial Readiness and Endpoint Assessment in Congenital Myotonic Dystrophy
Official title: Trial Readiness and Endpoint Assessment in Congenital Myotonic Dystrophy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Congenital Myotonic Dystrophy
Lead sponsor: Virginia Commonwealth University
Sponsor class: OTHER
Collaborators: name: Fondazione Serena Onlus - Centro Clinico NeMO Milano
name: University of Western Ontario, Canada, Children's Health Research Institute
First posted: 2017-02-23
Enrollment: 100
Sex: ALL
Minimum age (years): 0
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: This study proposes a longitudinal evaluation of 100 children with CDM and 50 healthy controls, stratified into the following age cohorts: 0-2 years, 11 months; 3 years to 6 years, 11 months; and 7 years and older. The age cohorts are created to ensure an even distribution across all ages.

Brief summary: Congenital Myotonic Dystrophy (CDM) is a multi-systemic, dominantly inherited disorder caused by a trinucleotide repeat expansion (CTGn) in the DMPK gene. CDM occurs when the CTGn increases between the adult myotonic dystrophy type-1 (DM1) parent and the child. Children with CDM present at birth with respiratory insufficiency, talipes equinovarus, feeding difficulties and hypotonia. There is a 30% mortality rate in the first year of life. As children grow, they are at risk for intellectual impairment, autistic features, gastrointestinal symptoms, and motor delay.

The investigators will enroll children with CDM between ages 0-15 with visits at baseline and one year to evaluate appropriate physical functional outcomes, cognitive function and quality of life over time. Functional outcome measures will be correlated with potential biomarkers in the children. Completion of these specific aims will extend the understanding of disease progression in CDM and will provide the requisite information for successful therapeutic trials in children with DM.


Eligibility criteria: CDM Group

Inclusion Criteria:

* Age 0-15 yrs
* Diagnosis of CDM, based on symptoms and genetic testing of expanded trinucleotide repeats.

Exclusion Criteria:

* Any other non-DM1 illness that would interfere with the ability or results of the study in the opinion of site investigator
* Significant trauma within one month
* Internal metal or devices

Control Group

Inclusion Criteria:

* Age 0-15 yrs
* Healthy children on no medication

Exclusion Criteria:

* Any illness or situation that, in the opinion of the site investigator, has the possibility to interfere with study procedures
* DM type 1 and 2

Primary outcomes:
measure: Grip Strength
timeFrame: 1 year
Secondary outcomes:
measure: Congenital and Childhood Onset Myotonic Dystrophy Health Index (CCMDHI)
timeFrame: 1 year
measure: 6-minute walk
timeFrame: 1 year
measure: Behavior Rating Inventory of Executive Function (BRIEF)
timeFrame: 1 year
measure: Lip Force
timeFrame: 1 year
Other outcomes:
Locations:
city: Richmond
country: United States
facility: Virginia Commonwealth University
state: Virginia
city: London
country: Canada
facility: Pediatric Neuromuscular Research, Children's Hospital - LHSC
state: Ontario
city: Milano
country: Italy
facility: Centro Clinico Nemo
Study officials:
affiliation: Virginia Commonwealth University
name: Nicholas Johnson, MD
role: PRINCIPAL_INVESTIGATOR
References: